Stocks · News reference
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Read original at benzingaCantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.
Read original at benzingaEvercore ISI Group analyst Umer Raffat initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating.
Read original at benzinga